USE OF TH9507 IN HIV INFECTED INDIVIDUALS WITH EXCESS ABDOMINAL FAT

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。HIV脂肪营养不良的特征是内脏脂肪过多、血脂异常和生长激素(GH)水平低下。TH9507是一种生长激素释放因子，生理性地增加生长激素水平。TH9507之前的一项研究表明，TH9507可以减少内脏脂肪组织(VAT)和躯干脂肪，增加瘦体重和改善血脂状况，总体耐受性良好。本研究旨在探讨TH9507治疗26周的疗效及其持续时间。主要结果是增值税的减少。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HIV lipodystrophy is characterized by excess visceral fat, dyslipidemia, and low growth hormone (GH) levels. TH9507 is a GH releasing factor that physiologically increases GH levels. A previous study of TH9507 resulted in decreases in visceral adipose tissue (VAT) and trunk fat, increases in lean body mass and lipid profile improvement, and was generally well-tolerated. This study is aimed at investigating the effects of TH9507 for 26 weeks and duration of these benefits. The primary outcome is reduction of VAT.